Cell Therapy

Stem Cell Transplants Extend Life for Multiple Myeloma Patients

Researchers at UC Davis have confirmed that autologous hematopoietic stem cell transplant improves survival for people suffering from multiple myeloma, yet many potentially eligible patients never undergo the procedure. Using data from two extensive California databases, the team showed median overall survival for transplant patients was around 73 months, while controls who did not receive the procedure lived around 50 months. The study was published June 11 in the Journal
Biotechnology

Researchers Explore Innovative Therapy for Treatment-Resistant Multiple Myeloma

New clinical trial investigates targeted treatment for incurable form of cancer A new clinical trial at Baylor Scott & White Research Institute is exploring a novel treatment option for patients with multiple myeloma, a type of cancer formed in bone marrow plasma cells that is considered incurable. The phase I trial will evaluate Actimab-M, developed by Actinium Pharmaceuticals, Inc., in treating patients with multiple myeloma who are unresponsive to available